Management

Focused on therapeutically relevant specialty pharmaceuticals

Management

Verity Pharma has a highly qualified team of pharmaceutical business executives, and scientists with greater than 20 years of international experience in the commercial and clinical aspects of prescription medicines. Verity is also supported by globally recognized scientific, clinical and healthcare business advisers.

Mr. Howard M. Glase: CEO & General Manager

Howard brings over twenty years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market... Read More

Howard brings over twenty years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research and scientific communications industries.

Acquired corporate pharmaceutical brand experiences include the launch of Cipro in Canada and Cipro IV for global markets. Additionally, Howard launched Cardizem CD in Canada and moved to the national commercial team in the USA (Sanofi) on the cardiovascular portfolio, with national responsibilities on Cardizem CD ($1.3 billion in sales) and led the launch of Teczem (Co-promoted with Merck) in the American hypertension market.

For the past 14 years, Howard has focused his entrepreneurial passion in developing healthcare businesses in the biotech and pharmaceutical industries. The successful entrepreneurial ventures included a scientific publishing business and a primary health science market research company. Howard has also been involved in providing health care consultation services to Canadian, American and Internationally based Pharmaceutical companies.

Howard studied at the University of Ottawa in Kinesiology and Health Sciences and completed a corporate-sponsored MBA certificate program in finance at Princeton University, NJ, and an executive MBA diploma course in International Business at University of Western Ontario, London, Ontario.

Read Less

Mr. Scott Doherty, CPA: Chief Financial Officer

Scott joins Verity with a background in strategic pharmaceutical planning, financial analytics, consulting, business development and tax planning within a multi national pharmaceutical organization. He achieved extensive executive decision-making accomplishments... Read More

Scott joins Verity with a background in strategic pharmaceutical planning, financial analytics, consulting, business development and tax planning within a multi national pharmaceutical organization. He achieved extensive executive decision-making accomplishments at Allergan Canada as the Senior Finance Manager, supporting senior management. During this time, Scott was responsible for overseeing the primary and specialty care business unit. Soon after, he was promoted to lead commercial analytics and planning within operations. There, his responsibilities included designing and implementing sales force compensation packages, business intelligence software, analytics and forecasting, as well as assessing ROI, resource sizing and allocation.
A CPA, Scott began his career in public accounting before becoming a senior financial analyst at a multi national traded company.

As the Verity CFO, Scott works within the Executive to contribute to the financial planning and governance of the company’s growth plans.

Read Less

Ms. Eryn Corriveau: Director of Regulatory Affairs, Quality Assurance, and Quality Control

Eryn Corriveau has over 25 years of experience in Canadian and Global pharmaceutical regulatory affairs. Eryn obtained her Master of Science degree in Human Physiology from the University of Toronto... Read More

Eryn Corriveau has over 25 years of experience in Canadian and Global pharmaceutical regulatory affairs. Eryn obtained her Master of Science degree in Human Physiology from the University of Toronto before pursuing her career in regulatory affairs. Her corporate background includes companies such as AstraZeneca, Boehringer Ingelheim, Serono and Sunovion.

Eryn has led numerous successful filings, from first in-human studies to marketing authorizations in a number of therapeutic areas including infectious disease, psychiatry, cardiovascular, respiratory, movement disorders, neurology, and urology. She joins the Verity team as Director of Regulatory Affairs.

Read Less

Mrs. Julie Amblard: V.P. Commercial Operations

Julie has over 20 years experience in the Canadian Pharmaceutical industry, ranging from Primary and Specialty Care, to Rare Disease and the Biotech segments.  Her focus has been Knowledge Management,... Read More

Julie has over 20 years experience in the Canadian Pharmaceutical industry, ranging from Primary and Specialty Care, to Rare Disease and the Biotech segments.  Her focus has been Knowledge Management, through the integration of Market Research, Secondary data and Financial/Operational Forecasting.

Her work has driven C-Level decisions for numerous fortune 50 pharmaceutical companies, by providing actionable insights to help shape strategy and direct execution for such companies as:   Glaxo SmithKline, Sanofi-Aventis, Novartis and Shire Pharmaceuticals. Julie has been the recipient of the Sanofi President`s award, the Novartis Commercial Excellence award for Innovative Patient Opportunity Assessment, and the Shire Circle of Excellence award.

From an academic perspective, Julie has been a guest lecturer on market research “From theory to Practice” for the Universities of Concordia and McGill’s Joint Pharmaceutical MBA Program, and for Les Hautes Etudes Commerciales (HEC) Montreal.  She co-authored and presented a market research paper on: “Demystifying Compliance in HIV” at an ‘EphMRA/ESOMAR conference’, and has been a guest speaker on several occasions at the ‘Annual US PHARMA-Market Research Conference’ on Innovative Customer focused solutions. Julie’s international experience was earned through a 5-year MBA professorship in France (CERAM), teaching Consumer Behavior, Marketing Research and consulting to the Banking industry. At this time, Julie finished her thesis on: A Convent in Crisis: The Ursuline’s Membership Decline”. Julie believes in harnessing the power of Market Intelligence and changing the status quo.

Read Less

Mr. Scott Bradford: Director of Marketing and Communications

With over 30 years of experience in Pharmaceutical and Consumer advertising, Scott brings a high level of insight, leadership, and commitment to excellence to every assignment, no matter how big... Read More

With over 30 years of experience in Pharmaceutical and Consumer advertising, Scott brings a high level of insight, leadership, and commitment to excellence to every assignment, no matter how big or how small.

Scott spent the first 18 years of his career as Art Director and Creative Director in some of Toronto’s top agencies. The next 16 years saw him take on the world of healthcare as Partner and VP-Creative Director of Commotion Communications, leading a team of account executives, medical writers, and designers, handling pharmaceutical and medical device clients in Canada and the U.S.

From brand strategy and planning, to creative development and execution, Scott’s experiences provide him with the ability to handle the creation and marketing of a successful brand from start to finish.

Read Less

Mr. Robert Rieder: Chairman

Mr. Rieder was most recently a founder and CEO of ESSA Pharmaceuticals, and was responsible for all aspects of the ESSA’s business. In that role, Mr. Rieder raised more than... Read More

Mr. Rieder was most recently a founder and CEO of ESSA Pharmaceuticals, and was responsible for all aspects of the ESSA’s business. In that role, Mr. Rieder raised more than $250 million of financing and took the Company public on the TSX and NASDAQ.

Previously, Mr. Rieder was the CEO of Cardiome Pharma Corp. (“Cardiome”), a public company traded on the TSX and NASDAQ. Mr. Rieder led Cardiome from the pre-clinical research stage to approval in the European Union while Cardiome negotiated partnerships with Merck and Astellas. Mr. Rieder has been a director for nine public and private technology companies. In 2009, he was acknowledged as “Executive of the Year” by Life Sciences B.C. and in 2007 was named Ernst & Young “Entrepreneur of the Year” for the Medical Products area in the Pacific Region.

Read Less

Mr. Allan Silber: Member of the Board

With respect to Mr. Silber’s health care companies, he was the Chairman of the Board of Capstone Pharmacy Services, Inc., an American institutional pharmacy services provider, and Stadtlander Drug Co.,... Read More

With respect to Mr. Silber’s health care companies, he was the Chairman of the Board of Capstone Pharmacy Services, Inc., an American institutional pharmacy services provider, and Stadtlander Drug Co., Inc., a specialty retail pharmacy organization.

Mr. Silber structured several financings and a public offering for Capstone, raising over US$100 million, as well as negotiating its merger with Pharmacy Corporation of America, creating PharMerica Inc., a transaction valued at US$840 million. Stadtlander was a leading US provider of disease specific pharmaceutical care to high risk, high cost patient populations including transplant recipients and HIV/AIDS, oncology and infertility patients. After significant growth and success under Mr. Silber’s leadership, Stadtlander was sold to Bergen Brunswig Corporation.

Mr. Silber has an extensive background in the private equity and financial services fields. He is currently the Chairman of the Board of Street Capital Group Inc., a Canadian public company that he founded in 1979. He is also the Chairman of the Board of Street Capital’s former subsidiary, Heritage Global Inc., a U.S. public company and United States Security and Exchange Commission registrant. He has founded and managed a number of companies as well as led many mergers, acquisitions and financings.

Mr. Silber is actively involved in several cultural, charitable and community-based organizations, including participation at the board level, and has been chairman of numerous fundraising events for community-based and international organizations. He has been recognized for his philanthropic work by the Jewish National Fund, in regards to community leadership and dedication to public service. Mr. Silber attended McMaster University and received a BSc from the University of Toronto.

Read Less